CHARM Therapeutics
LONDON, X0 · Biotechnology, Healthcare, Health Care · 35 employees
CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.
Funding history
- Venture - Series Unknown — $17.3M — Sep 2025
- Series B — $80.0M — Sep 2025
- Venture - Series Unknown — $20.0M — Apr 2023
- Venture - Series Unknown — $37.0M — Jun 2022
- Venture - Series Unknown — $12.6M — Oct 2021
Recent signals
- Sep 03, 2025: Raised $17.3M in Venture - Series Unknown
- Sep 02, 2025: Raised $80.0M in Series B
- Sep 10, 2024: CHARM Therapeutics Appoints Dr Beverley Carr as Chief Business Officer
- Apr 30, 2024: CHARM Therapeutics Appoints Dr. Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development
- Apr 14, 2023: Raised $20.0M in Venture - Series Unknown
- Jun 24, 2022: Raised $37.0M in Venture - Series Unknown
- Oct 22, 2021: Raised $12.6M in Venture - Series Unknown
See plans & pricing → Track CHARM Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.